|
HA protein-based vaccine
|
Novavax, Inc.
|
HA Rosettes, HA nanoparticles, VLP with Matrix-MTM adjuvant
|
I/II
|
Particle format for potency, multiple strains mixed or sequential delivery; HAI and MN assay
|
[45,46,47]
|
|
NIH, GSK, and Icahn School of Medicine at Mount Sinai
|
HA stem or head-stem chimera
|
I
|
bnAbs (no HAI) and ADCC; intranasal influenza challenge
|
[48,49,50,51]
|
|
Academia Sinica and OPKO
|
Monoglycosylated HA as universal flu vaccine, exposing the conserved domain to elicit bnAbs
|
preclinical
|
Broad cross-reactive Ab; HAI and MN assay
|
[52,53,54]
|
|
Epitope-peptides based vaccine
|
BiondVax Pharmaceuticals Ltd
|
HA, NP, M1 peptides
|
II/III
|
Cytotoxic T lymphocytes (CTL) response
|
[55,56,57,58]
|
|
PepTcell.Ltd
|
FLU-V
|
II
|
Cross-reactive T-cell responses, and mucosal immunity; intranasal influenza challenge
|
[59,60,61,62,63]
|
|
Live attenuated virus vaccine
|
CodageniX
|
CodaVax Live-attenuated and single-round whole virus
|
I/II
|
Additional antigens, T cell responses, and mucosal immunity; intranasal influenza challenge
|
[64,65,66]
|
|
FluGen
|
M2SR
|
I/II
|
T cell responses, and mucosal immunity; intranasal influenza challenge
|
[67, 68]
|
|
DNA based vaccine
|
Inovio
|
RNA, DNA, or vector subunit delivery
|
I
|
Gene delivery for CTL and Ab
|
[69,70,71,72]
|
|
M2-based protein vaccine
|
Acambis/Sanofi Pasteur
|
M2 ectodomain
|
I/II
|
bnAbs; ADCC (no NT); intranasal influenza challenge
|
[73, 74]
|
